期刊文献+

垂体微腺瘤动态增强MRI的临床应用 被引量:4

Dynamic enhanced MRI imaing in disgnosis of pituitary microadenomas with prolactin (PRL) secretion
下载PDF
导出
摘要 目的评价垂体微腺瘤动态增强MBI的临床应用价值.方法回顾性分析48例经手术或临床证实的泌乳激素(PRL)分泌型垂体微腺瘤的动态增强MRI资料,并经处理后获得其对比增强率-时间(CER-T)曲线类型和增强峰值(EP),将其检出率与常规平扫及常规增强扫描微腺瘤的检出率进行比较.结果48例微腺瘤CER-T曲线类型分布:Ⅰ型0例,Ⅱ型7例,Ⅲ型6例,Ⅳ型19例和Ⅴ型16例.微腺瘤EP值在90~180 s内13例,在180 s以后25例.动态增强MRI检出率为95.8%(46/48),其中60 s时腺瘤与正常垂体对比效果最为明显,检出效率为58.3%(28/48).常规平扫检出率为25.0%(12/48).常规增强MRI检出率为52.1%(25/48).行×列x2检验,P<0.01.结论动态增强扫描是诊断PRL分泌型垂体微腺瘤的可靠方法,临床和实验室检查怀疑PRL型微腺瘤而MRI平扫阴性者,动态MRI应列为常规检查. [objective] To investigate the use of dynamic enhanced MRI imaging in evaluation of pituitary microadenomas. [Methods] The MRI date of 48 patients with PRL secretion pituitary microadenomas proved by operation or clinical findings were retrospectively studied by radiologists, compare diagnostic rate of dynamic enhanced MRI with conventional contrast enhanced MRI and unenhanced MRI. The contrast enhancement ratio-time (CER-T) curves type and enhancement (EP) were obtained by postprocessing. [Results] The CER-T curves type as follows: The type I in 0 case, type II in 7 cases, type III in 6 cases, type IV in 19 cases and type V in 16 cases. EP during 90~180 s was 13 cases and 25 cases over 180 s. The diagnostic rate of dynamic enhanced MRI was 95.8% (46/48), among 58.3% (28/48) in 60 s. The diagnostic rate of conventional enhanced MRI and unenhanced MRI was 52.1% (25/48) and 25.0% (12/48), (P<0.01). [Conclusions] Dynamic enhanced MRI is valuable in diagnosing PRL secrection pituitary microadenomas, so it should become routine examination of PRL secrection pituitary microadenomas which is suspected by clinic or laboratory finding but negative in conventional MRI.
作者 姜新雅 仇斌
出处 《中国现代医学杂志》 CAS CSCD 北大核心 2005年第11期1715-1717,共3页 China Journal of Modern Medicine
关键词 垂体腺瘤 MRI pituitary adenoma MRI
  • 相关文献

参考文献6

二级参考文献40

  • 1卢光明,杨刚,张福琛,沈复兴,王昌新.动态增强MRI诊断垂体微腺瘤的研[J].中华放射学杂志,1996,30(5):329-332. 被引量:39
  • 2朱文珍,王承缘,漆剑频,陈荣萍,胡军武,冯定义,王锦芳.垂体的半剂量Gd-DTPA增强磁共振成像研究——与全剂量及手术病理对照分析[J].临床放射学杂志,1997,16(1):5-8. 被引量:2
  • 3Jensen RL. Growth factor - mediated angiogenesis in the malignant progression of glial tumors:a review. Surg Neurol, 1998;49(1):189-- 196.
  • 4Turner HE , et al. Angiogenesis in pituitary adenomas - relationship to endocrine function, treamaent and outcome. Journal of Endocrinology, 2000; 165(2) :475-481.
  • 5Knosp E, Steiner E, Kitz K, et al. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings . Neurosurgery, 1993;33 (4):610--618.
  • 6Weidner N. Intratumor microvessel density as prognosic factor in cancer. Am J Pathol, 1995;147(1):9~19.
  • 7Folkman J. Tumor angiogenesis: Therapeutic implication . N Eag J Med, 1971 ;285(22) : 1182-1186.
  • 8Hanahan D, Folkman J. Patterns and emerging mechanisms of the ngiogenic switch during tumorigenesis. Cell, 1996; 86 (2) : 353-364.
  • 9Hughes SE, Hall PA. Overview of the fibrobhst growth factor and receptor families: complexity, functional diversity,mad implications for future cardio- vascular research. Cardiovasc Res, 1993;27(7):1199-1203.
  • 10David Zagzag. Angiogenic growth factors or neural embryogeneses and neoplasia. American Journal of Pathology, 1995; 146 (2) : 293--309.

共引文献25

同被引文献36

引证文献4

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部